Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Apr 2018

Dunn David T, Stöhr Wolfgang, Arenas-Pinto Alejandro, Tostevin Anna, Mbisa Jean L, Paton Nicholas I

Abstract excerpt

BACKGROUND: The PIVOT trial examined whether patients with suppressed viral load on combination antiretroviral therapy could be safely switched long-term to ritonavir-boosted protease inhibitor (PI) monotherapy. The main trial publication reported that only one of 296 patients allocated to PI monotherapy experienced a loss of drug options due to protease mutations (identified by local Sanger sequencing resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to England

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Sequence Analysis, RNA

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 29428459
DOI: 10.1016/j.jcv.2018.02.003
PMCID: PMC5861306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.PMID 29428459Read ↗

Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.Semantic proximity Read ↗

In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.Semantic proximity Read ↗

Next-Generation Sequencing Reveals a High Frequency of HIV-1 Minority Variants and an Expanded Drug Resistance Profile among Individuals on First-Line ART.Semantic proximity Read ↗

Next Generation Sequencing Reveals a High Prevalence of HIV-1 Minority Variants and an Expanded Drug Resistance Profile Among Individuals Initiated to Antiretroviral Therapy in a Resource-constrained SettingSemantic proximity Read ↗

Next-generation sequencing reveals major and minority HIV-1 drug resistance mutations in treatment-experienced individuals with virological failure.Semantic proximity Read ↗

Genotypic resistance testing in routine clinical care.Semantic proximity Read ↗

HIV-1 genotypic drug resistance testing: digging deep, reaching wide?Semantic proximity Read ↗

In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 MatrixSemantic proximity Read ↗

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.Semantic proximity Read ↗

Limited marginal utility of deep sequencing for HIV drug resistance testing in the age of integrase inhibitorsSemantic proximity Read ↗

Evaluation of Vela Diagnostics HIV-1 genotyping assay on an automated next generation sequencing platform.Semantic proximity Read ↗

RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.